



## **BSW Formulary Updates and Recent Decisions – July 2025**

### **New additions to BSWformulary and Change in Traffic Light Status (TLS)**

- [Rifaximin for small intestinal bacterial overgrowth \(SIBO\) off-label use](#) – added to formulary with **RED** traffic light with wording to highlight this is for a one-off 10 day course following failure of conventional treatment.

### **New and Updated Prescribing Guidelines and Shared Care Agreements**

- [Colomycin in non-CF Bronchiectasis](#) – changed from SCA to prescribing guidance and traffic light changed to **AMBER**. Approved for publication.
- [CKD Management Guidance \(BNSSG\)](#) – approved for publication and use across BSW after clarification on a few points.

### **Minor amendments to Netformulary**

- a few products have been debranded and generics are available, including Otomize, Caverject and ambisome.
- Champix is available again but generic prescribing should continue.
- Shortage of bumetanide 1mg tablets, wording was added to formulary entry that no new patients should be initiated on this strength.
- Tolak added as an alternative to Efudix during shortages but they are not exactly equivalent products and have differing licenses.
- Vitamin D guidance – this has been updated and published on the website.

### **What the BSW ICB formulary team are currently working on**

- Testosterone in men shared care agreement
- Insulin formulary update
- Cost effective dapagliflozin switch
- Producing an amiodarone SCA

*The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email [bswicb.formulary@nhs.net](mailto:bswicb.formulary@nhs.net)*